|

Tamoxifen Clinical Trials

23 actively recruiting trials across 14 locations

Also known as: Nolvadex, Nolvadex®, Soltamox, TMX

Other8 trials

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
Phase 3
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
Phase 2
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
Phase 2
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Phase 3
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
Phase 3
Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients
Phase 3
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
Early 1
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
Phase 2

St Louis, Missouri2 trials

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Washington University School of Medicine

Phase 2
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Siteman Cancer Center at Washington University

Phase 2

Birmingham, Alabama1 trial

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Research Site

Phase 3

Daphne, Alabama1 trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Southern Cancer Center, PC

Phase 3

Dothan, Alabama1 trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Research Site

Phase 3

Anchorage, Alaska1 trial

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Alaska Womens Cancer Care ( Site 0037)

Phase 2

Tucson, Arizona1 trial

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

University of Arizona Cancer Center - Prevention Research Clinic

Phase 2

Berkeley, California1 trial

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Berkeley Outpatient Center

Phase 2

Duarte, California1 trial

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

City of Hope Comprehensive Cancer Center

Phase 2

San Francisco, California1 trial

Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

University of California at San Francisco

Phase 3

Washington D.C., District of Columbia1 trial

ETHAN - ET for Male BC

Georgetown University Medical Center

Phase 2

Kansas City, Kansas1 trial

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

University of Kansas Cancer Center

Phase 2

Buffalo, New York1 trial

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 2

Houston, Texas1 trial

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

M D Anderson Cancer Center

Phase 2

Madison, Wisconsin1 trial

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

University of Wisconsin Carbone Cancer Center

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.